Skip NavigationSkip to Content
Return Return to Search Results

Advances in using PARP inhibitors to treat cancer

  1. Author:
    Kummar, S.
    Chen, A.
    Parchment, R. E.
    Kinders, R. J.
    Ji, J.
    Tomaszewski, J. E.
    Doroshow, J. H.

  2. Author Address

    [Kummar, Shivaani; Chen, Alice; Tomaszewski, Joseph E.; Doroshow, James H.] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA. [Parchment, Ralph E.; Kinders, Robert J.; Ji, Jay] NCI, Sci Applicat Int Corporat Frederick Inc, Appl Dev Res Directorate, Frederick, MD 21702 USA. [Doroshow, James H.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA.;Doroshow, JH (reprint author), NCI, Div Canc Treatment & Diag, Bldg 31,Room 3A-44,31 Ctr Dr, Bethesda, MD 20892 USA;doroshoj@mail.nih.gov
    1. Year: 2012
    2. Date: Mar
  2. Journal: Bmc Medicine
    1. 10
  4. Type of Article: Review
  5. Article Number: 25
  6. ISSN: 1741-7015
  1. Abstract:

    The poly (ADP-ribose) polymerase (PARP) family of enzymes plays a critical role in the maintenance of DNA integrity as part of the base excision pathway of DNA repair. PARP1 is overexpressed in a variety of cancers, and its expression has been associated with overall prognosis in cancer, especially breast cancer. A series of new therapeutic agents that are potent inhibitors of the PARP1 and PARP2 isoforms have demonstrated important clinical activity in patients with breast or ovarian cancers that are caused by mutations in either the BRCA1 or 2 genes. Results from such studies may define a new therapeutic paradigm, wherein simultaneous loss of the capacity to repair DNA damage may have antitumor activity in itself, as well as enhance the antineoplastic potential of cytotoxic chemotherapeutic agents.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1186/1741-7015-10-25
  3. View record in Web of Science®
  4. WOS: 000301944900001

Library Notes

  1. Fiscal Year: FY2011-2012
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel